Intervention not reported
Grade 3 to 4 rash · people with metastatic colorectal cancer ‐ KRAS exon 2 MT
The intervention probably leads to higher grade 3 to 4 rash (moderate certainty).
1 finding from 1 review
Intervention not reported
Grade 3 to 4 rash · people with metastatic colorectal cancer ‐ extended RAS WT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Grade 3 to 4 rash · people with metastatic colorectal cancer ‐ extended RAS MT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Grade 3 to 4 rash · people with metastatic colorectal cancer, not selected by KRAS status
1 finding from 1 review
Intervention not reported
Grade 3 to 4 rash · people with metastatic colorectal cancer
The intervention probably leads to higher grade 3 to 4 rash (moderate certainty).
1 finding from 1 review
Intervention not reported
Grade 3 to 4 rash · people with metastatic colorectal cancer, not selected by KRAS status
1 finding from 1 review
Intervention not reported
Grade 3 to 4 rash · people with metastatic colorectal cancer ‐ KRAS exon 2 WT
The intervention probably leads to higher grade 3 to 4 rash (moderate certainty).
1 finding from 1 review
Intervention not reported
Grade 3 to 4 rash · people with metastatic colorectal cancer, not selected by KRAS status
1 finding from 1 review
Intervention not reported
Grade 3 to 4 rash · people with metastatic colorectal cancer
The intervention probably leads to higher grade 3 to 4 rash (moderate certainty).
1 finding from 1 review
Grade 3 to 4 rash · treatment of relapsed epithelial ovarian cancer
It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes toxicity: grade 3 or 4 rash compared with chemotherapy alone (very low certainty).
1 finding from 1 review